Lincoln Pharmaceuticals Ltd
Incorporated in 1979, Lincoln Pharmaceuticals Ltd is in the business of manufacturing and trading of pharmaceutical products [1]
- Market Cap ₹ 1,165 Cr.
- Current Price ₹ 581
- High / Low ₹ 980 / 499
- Stock P/E 14.1
- Book Value ₹ 335
- Dividend Yield 0.31 %
- ROCE 17.6 %
- ROE 13.0 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
- Company is almost debt free.
Cons
- The company has delivered a poor sales growth of 10.0% over past five years.
- Dividend payout has been low at 4.12% of profits over last 3 years
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Part of BSE Healthcare BSE SmallCap BSE Allcap
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 210 | 266 | 400 | 360 | 361 | 366 | 386 | 424 | 472 | 510 | 581 | 623 | |
| 190 | 240 | 359 | 313 | 308 | 299 | 321 | 337 | 376 | 421 | 480 | 522 | |
| Operating Profit | 20 | 26 | 41 | 47 | 53 | 68 | 66 | 87 | 96 | 90 | 100 | 101 |
| OPM % | 10% | 10% | 10% | 13% | 15% | 18% | 17% | 21% | 20% | 18% | 17% | 16% |
| 2 | 7 | 7 | 2 | 5 | 5 | 11 | 5 | 10 | 22 | 34 | 22 | |
| Interest | 7 | 8 | 10 | 7 | 5 | 4 | 2 | 2 | 1 | 2 | 1 | 2 |
| Depreciation | 4 | 5 | 5 | 6 | 6 | 7 | 7 | 8 | 8 | 9 | 11 | 13 |
| Profit before tax | 12 | 20 | 33 | 37 | 46 | 62 | 67 | 84 | 96 | 100 | 122 | 109 |
| Tax % | 16% | 24% | 28% | 25% | 25% | 22% | 23% | 26% | 28% | 27% | 24% | 25% |
| 10 | 15 | 24 | 28 | 35 | 49 | 51 | 62 | 69 | 73 | 93 | 82 | |
| EPS in Rs | 6.53 | 9.20 | 14.52 | 14.06 | 17.31 | 24.36 | 25.72 | 31.12 | 34.63 | 36.40 | 46.58 | 41.11 |
| Dividend Payout % | 9% | 11% | 7% | 9% | 9% | 6% | 6% | 5% | 4% | 4% | 4% | 4% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 10% |
| TTM: | 7% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 19% |
| 5 Years: | 10% |
| 3 Years: | 6% |
| TTM: | -11% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 23% |
| 5 Years: | 29% |
| 3 Years: | 25% |
| 1 Year: | -5% |
| Return on Equity | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | 16% |
| 3 Years: | 15% |
| Last Year: | 13% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 16 | 16 | 16 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 | 20 |
| Reserves | 82 | 95 | 124 | 172 | 204 | 249 | 293 | 346 | 413 | 482 | 573 | 652 |
| 68 | 76 | 78 | 64 | 61 | 34 | 5 | 1 | 2 | 2 | 1 | 0 | |
| 93 | 70 | 56 | 48 | 62 | 63 | 71 | 85 | 99 | 83 | 106 | 125 | |
| Total Liabilities | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 |
| 65 | 66 | 98 | 103 | 117 | 121 | 123 | 111 | 132 | 151 | 179 | 182 | |
| CWIP | 2 | 3 | 3 | 7 | 0 | 2 | 0 | 2 | 16 | 7 | 3 | 4 |
| Investments | 0 | 0 | 0 | 10 | 11 | 18 | 34 | 81 | 97 | 91 | 139 | 174 |
| 192 | 190 | 174 | 186 | 219 | 225 | 232 | 259 | 290 | 339 | 379 | 437 | |
| Total Assets | 260 | 258 | 275 | 305 | 347 | 366 | 389 | 452 | 534 | 587 | 700 | 797 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5 | 25 | 45 | 25 | 27 | 53 | 75 | 69 | 76 | 39 | 63 | 93 | |
| 1 | 7 | -42 | -25 | -12 | -18 | -31 | -64 | -78 | -37 | -57 | -79 | |
| -11 | -32 | -3 | 0 | -11 | -36 | -38 | -6 | -3 | -4 | -5 | -6 | |
| Net Cash Flow | -4 | -1 | -0 | -0 | 3 | -1 | 7 | -1 | -4 | -2 | 1 | 8 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 154 | 163 | 73 | 92 | 111 | 122 | 96 | 98 | 90 | 98 | 102 | 97 |
| Inventory Days | 62 | 44 | 36 | 63 | 86 | 75 | 95 | 86 | 121 | 106 | 101 | 99 |
| Days Payable | 174 | 92 | 40 | 54 | 82 | 92 | 102 | 105 | 120 | 77 | 95 | 106 |
| Cash Conversion Cycle | 43 | 116 | 70 | 100 | 115 | 106 | 88 | 78 | 91 | 126 | 108 | 90 |
| Working Capital Days | 97 | 145 | 79 | 115 | 138 | 143 | 130 | 119 | 115 | 123 | 128 | 217 |
| ROCE % | 11% | 15% | 21% | 19% | 19% | 23% | 22% | 25% | 24% | 22% | 22% | 18% |
Documents
Announcements
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
23 May - Copies of published newspaper advertisement with respect to Audited (Standalone & Consolidated) Financial Results of the Company for the Quarter and Year ended March 31, …
- Corporate Action-Board approves Dividend 22 May
-
Audited Financial Results For The Quarter And Year Ended 31St March, 2025
22 May - Audited FY25 results with 18% dividend recommended; unmodified audit opinion, no exceptional items.
-
Board Meeting Outcome for Audited Financial Results For The Quarter And Year Ended 31St March, 2025
22 May - Audited FY25 results with 18% dividend recommended; revenue ₹62,323L, net profit ₹8,235L.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
17 May - Submission of annual secretarial compliance report for FY ended March 31, 2025.
Annual reports
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
-
Financial Year 2010
from bse
Concalls
-
Feb 2025TranscriptNotesPPT
-
Nov 2024TranscriptNotesPPT
-
Jun 2024TranscriptNotesPPT
-
May 2024Transcript PPT REC
-
Feb 2024TranscriptNotesPPT
-
Oct 2023TranscriptNotesPPT
-
Feb 2023TranscriptNotesPPT
-
Nov 2022TranscriptNotesPPT
-
Jul 2022TranscriptNotesPPT
-
Apr 2021TranscriptNotesPPT
-
Jan 2021TranscriptNotesPPT
-
Oct 2020TranscriptNotesPPT
-
Jul 2020TranscriptNotesPPT
-
Apr 2020TranscriptNotesPPT
-
Jan 2020TranscriptNotesPPT
-
Oct 2019TranscriptNotesPPT
-
Jul 2019TranscriptNotesPPT
-
Apr 2019TranscriptNotesPPT
-
Jan 2019TranscriptNotesPPT
-
Oct 2018TranscriptNotesPPT
-
Jul 2018TranscriptNotesPPT
-
Apr 2018TranscriptNotesPPT
-
Jan 2018TranscriptNotesPPT
-
Oct 2017TranscriptNotesPPT
-
Jul 2017TranscriptNotesPPT
-
Aug 2016TranscriptNotesPPT
Product Profile:[1]
LPL has developed 600+ formulations in 15 therapeutic areas and has 1700
registered products with another 700 in the pipeline. It also has 7 patented products and has filed applications for 25+ patents